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Abstract
nephrotoxicity is observed in 1.6 % of patients treated
with tenofovir disoproxil fumarat (fux 2007). 
cAsE REPoRT
we report a 37 year old late presenting HIv positive
male patient. He was admitted with wasting, chronic di-
arrhoea  and  oesophageal  candidiasis.  serology  con-
firmed  HIv-1  infection,  viral  load  was  55.000  copies
/ml(Abbott Realtime HIv-1, RT-PcR). cd4 + cells
were 77 /μl, and the cd4/cd8 ratio was 0.11. An
agenesis of the right kidney with a contra-lateral hyper-
trophy was detected by abdominal ultrasound. Howev-
er, normal values for creatinine (75 ﾵmol/l) and urea
(5.6 mmol/l) did not suggest an impaired renal func-
tion (gfR-MdRd 108 ml/min). In addition, history
revealed no risk factors for renal insufficiency (no dia-
betes  mellitus,  non-smoker,  no  hypertension).  con-
comitant medication did not contain drugs in appropri-
ate doses with  known high potential for nephrotoxicity
(trimethoprim  160mg  three  times  per week,  sulfa  -
metho  xazol  800mg three times per week, folic acid 5
mg twice daily, diflucan 100mg  daily, ceftriaxon 2g dai-
ly, pantoprazol 40 mg twice daily, enoxaparin 40 mg s.c.
daily, mirta  zapin 15 mg daily). Because of the high viral
load and the detoriated clinical condition we decided to
start an antiretroviral regimen as soon a possible. since
HlA-B5701 test result was pending, Abacavir was not
an option and we started with tenofovir, emtricitabin
plus  ralte  gravir to achieve fast reduction of viral load
(lennox 2009). An extensive literature research did not
reveal any data on tenofovir in patients with renal agen-
esis. 
Two days after initiation of ART laboratory moni-
toring of the renal function showed steadily increasing
values for urea and creatinine reaching maximal levels
of 14.2 mmol/l and 172 ﾵmol/l, respectively on day 6
despite intravenous volume substitution (gfR-MdRd
41.5ml/min). The patient developed acute kidney in-
jury  according  to  the  RIflE  criteria  (Bellomo  2004)
when HlA-B5701 was tested to be negative; the nRTI
backbone  was  switched  from  tenofovir  plus  emtric-
itabin to abacavir plus lamivudin. After discontinuation
of tenofovir renal parameters restored within 36 hours
to  baseline  values  (gfR-MdRd  104.5  ml/min)  and
remained at normal values during the further curse.
The most frequent mechanism of tenofovir induced
kidney failure is supposed to be tubular necrosis due to
mitochondrial  toxicity.  Tubular  necrosis  can  result  in
hypophosphataemia,  glucosuria,  and  in  a  decrease  of
gfR due to intrarenal feed back mechanisms (e.g. by
vasoconstriction  of  the  vas  afferens).  A  recent  renal
biopsy study in 13 cases of tenofovir nephrotoxicity re-
vealed  toxic  acute  tubular  necrosis,  with  distinctive
proximal  tubular  eosinophilic  inclusions  representing
giant mitochondria visible by light microscopy (Herlitz
2010). Electron microscopy showed mitochondrial en-
largement, depletion, and dysmorphic changes.  As in
our case significant recovery of renal function occurred
in all these patients after discontinuation of tenofovir,
including  in  four  patients  who  required  transient  he-
modialysis. 
since  its  introduction  in  2001  the  nucleotide  ana-
logue tenofovir is one of the most frequently used sub-
stances in HIv treatment. our case showed that teno-
fovir can induce a renal damage in patients with renal
agenesis  despite  initially  non-impaired  renal  function.
due to our experience we suggest that tenofovir should
not be used in these patients regardless of a normal re-
nal function.  
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